In this episode of the podcast, Joe Moore interviews Josh Hardman, the Founder and Editor of Psilocybin Alpha, a news website and weekly newsletter covering the psychedelic space with a focus on emerging companies and drug development. He talks about how the 2020 US election jumpstarted the site, especially due to the passing of Oregon’s Measure 109 and people suddenly showing a lot of interest in psychedelic stocks. And they discuss much more: why the UK is so conservative when it comes to drug policy; Brexit; cryptocurrency, decentralized finance (DeFi), and decentralized health; overuse of Sonoran desert toads and over-harvesting of iboga; data collection and data privacy; patent thicketing; integration as a new recurring-revenue model; psychedelics and VR; investor obsession with derivatives and analogs; and 2022 seeing the likely consolidation of many for-profit companies in the psychedelic space.

The post PT287 – Josh Hardman – Psychedelic Stocks, Data Privacy, and Drug Development appeared first on Psychedelics Today.

Previous articleFDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder
Next articleAwakn Life Sciences Files Patent Application for a New Class of Entactogen-Like Molecules to Treat a Broad Range of Addictions